Instil Bio Inc

NASDAQ:TIL   2:21:07 PM EDT
1.34
-0.06 (-4.64%)
Earnings Announcements

Instil Bio Reports Third Quarter 2022 Financial Results

Published: 11/14/2022 21:53 GMT
Instil Bio Inc (TIL) - Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
Confirms Cash Runway Into 2025 With Anticipated Sale-leaseback Transaction of Its Tarzana Manufacturing Facility.
Qtrly Net Loss per Share, Basic and Diluted $0.43.
First Patient With Non-small Cell Lung Cancer Dosed With Itil-306 With Plans to Share Clinical Data in 2023.
Q3 Earnings per Share View $-0.44 -- Refinitiv Ibes Data (analyst estimates).
Reprioritization of Resources With Enrollment Deferred in Delta-2 Trial of Itil-168.
Manufacturing Update on Voluntary Pause of Delta-1 Trial of Itil-168 in Advanced Melanoma Expected in Q1'23.
Revenue is expected to be $0.33 Million
Adjusted EPS is expected to be -$0.43

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.47

More details on our Analysts Page.